• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Diabetes therapy >Clinical Effects of Liraglutide in a Real-World Setting in Spain: eDiabetes-Monitor SEEN Diabetes Mellitus Working Group Study
【24h】

Clinical Effects of Liraglutide in a Real-World Setting in Spain: eDiabetes-Monitor SEEN Diabetes Mellitus Working Group Study

机译：Liraglutide在西班牙真实世界环境中的临床疗效：Edibetes-Monitor看到糖尿病Mellitus工作组研究

获取原文
获取原文并翻译 | 示例
       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Introduction: A limitation with randomized controlled trials is that, while they provide unbiased evidence of the efficacy of interventions, they do so under unreal conditions and in a very limited and highly selected patient population. Our aim was to provide data about the effectiveness of liraglutide treatment in a real-world and clinical practice setting. Methods: In a retrospective and observational study, data from 753 patients with type 2 diabetes were recorded through an online tool (eDiabetes-Monitor). Results: Mean baseline glycated hemoglobin (HbA1c) was 8.4 ± 1.4% and mean body mass index (BMI) was 38.6 ± 5.4 kg/m2. After 3–6 months of treatment with liraglutide, we observed a change in HbA1c of ?1.1 ± 1.2%, ?4.6 ± 5.3 kg in weight and ?1.7 ± 2.0 kg/m2 in BMI (p < 0.001 for all). Compared to baseline, there was a significant reduction in systolic blood pressure (?5.9 mmHg, p < 0.001), diastolic blood pressure (?3.2 mmHg, p < 0.001), LDL cholesterol (?0.189 mmol/l, p < 0.001) and triglycerides (?0.09 mmol/l, p = 0.021). In patients switched from DPP-4 inhibitors, liraglutide induced a decrease of ?1.0% in HbA1c (p < 0.001) and a reduction in weight (?4.5 kg, p < 0.001). In patients treated with liraglutide as an add-on therapy to insulin a decrease of ?1.08% in HbA1c (p < 0.001) and a weight reduction of ?4.15 kg (p < 0.001) were observed. Conclusion: Our study confirms the effectiveness of liraglutide in a real-life and clinical practice setting. Funding: Spanish Society of Endocrinology and Nutrition.
机译：介绍：随机对照试验的限制是，虽然它们提供了不偏见的干预效果的证据，但在虚幻条件下，它们在非常有限和非常选定的患者人口下。我们的目的是提供有关Liraglutide治疗在现实世界和临床实践环境中的有效性的数据。方法：在回顾性和观察性研究中，通过在线工具（EdiaBetes-Monitor）记录来自753型糖尿病患者的数据。结果：平均基线糖化血红蛋白（HBA 1C ）为8.4±1.4％，平均体重指数（BMI）为38.6±5.4 kg / m 2。经过3-6个月的黎棱镜治疗后，我们观察了HBA 1C 的变化？1.1±1.2％，重量和α4.6±5.3千克，BMI中的1.7±2.0 kg / m2（p <0.001对于全部）。与基线相比，收缩压（Δ5.9mmHg，p <0.001），舒张压（β3.2mmHg，p <0.001），LDL胆固醇（α0.189mmol/ L，p <0.001）和甘油三酯（β09mmol/ L，p = 0.021）。在从DPP-4抑制剂转换的患者中，丽菌蛋白质在HBA 1C （P <0.001）中诱导α1.0％的减少，减少重量（Δ4.5kg，p <0.001）。在患有黎拉蛋白质作为胰岛素的加入治疗治疗的患者中，HBA 1C>（P <0.001）中的减少α1.08％，并观察到Δ4.15kg（p <0.001）的重量减少。结论：我们的研究证实了Liraglutide在现实生活和临床实践环境中的有效性。资金：西班牙民族内分泌学会和营养。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号